Stanisławiak-Rudowicz Joanna, Szałek Edyta, Więckowska Barbara, Grześkowiak Edmund, Mądry Radosław
Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, Poznań, Poland.
Department of Gynaecological Oncology, Poznań University Clinical Hospital, Szamarzewskiego 84, Poznań, Poland.
Pharmacol Rep. 2025 Apr;77(2):500-507. doi: 10.1007/s43440-025-00702-z. Epub 2025 Jan 29.
Olaparib is a relatively new poly(ADP-ribose) polymerase inhibitor (PARPi) administered to ovarian cancer (OC) patients with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is the disruption of glucose homeostasis, often resulting in hyperglycemia The study was a retrospective analysis of olaparib-induced hyperglycemia in OC patients with initial normoglycemia following the first, second, and third month of olaparib treatment METHODS: The study involved 32 OC patients, classified into three groups according to their Body Mass Index (BMI): normal BMI (BMI 18.5-24.9 kg/m; n = 13), overweight (BMI 25-29.9 kg/m; n = 13), and obese (BMI ≥ 30 kg/m; n = 6). The fasting glucose (FG) concentration was evaluated after the first, second, and third cycle of olaparib treatment (a cycle is the equivalent of 28 days of treatment). The severity of the observed hyperglycemia was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
A significant increase in glycemia was observed after the first and second cycles of olaparib treatment in the group with normal BMI and after the third cycle in overweight and obese patients. There were no significant differences in glucose levels among the groups following the first, the second, and the third cycle. Grade 1 hyperglycemia with impaired fasting glucose levels (5.6-6.9 mmol/l) was found in 15 patients (normal BMI: n = 4, overweight: n = 9, and obesity: n = 2), while glycemia typical of diabetes (≥ 7.0 mmol/l) was observed in one obese patient.
Regardless of the weight of OC patients, it is essential to control glycemia during olaparib treatment.
奥拉帕利是一种相对较新的聚（ADP - 核糖）聚合酶抑制剂（PARPi），用于治疗对一线化疗有完全或部分反应的卵巢癌（OC）患者。奥拉帕利的代谢副作用之一是破坏葡萄糖稳态，常导致高血糖。本研究是对奥拉帕利治疗第一、第二和第三个月后初始血糖正常的OC患者中奥拉帕利诱导的高血糖进行的回顾性分析。方法：该研究纳入32例OC患者，根据体重指数（BMI）分为三组：正常BMI（BMI 18.5 - 24.9 kg/m²；n = 13）、超重（BMI 25 - 29.9 kg/m²；n = 13）和肥胖（BMI≥30 kg/m²；n = 6）。在奥拉帕利治疗的第一、第二和第三个周期（一个周期相当于28天治疗）后评估空腹血糖（FG）浓度。使用不良事件通用术语标准（CTCAE v5.0）评估观察到的高血糖的严重程度。结果：正常BMI组在奥拉帕利治疗的第一和第二个周期后以及超重和肥胖患者在第三个周期后血糖显著升高。在第一、第二和第三个周期后，各组之间的血糖水平无显著差异。15例患者出现空腹血糖受损（5.6 - 6.9 mmol/l）的1级高血糖（正常BMI：n = 4，超重：n = 9，肥胖：n = 2），而1例肥胖患者出现典型糖尿病血糖（≥7.0 mmol/l）。结论：无论OC患者体重如何，在奥拉帕利治疗期间控制血糖至关重要。
